ProfileGDS5678 / 1428183_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 4% 84% 80% 4% 4% 4% 4% 4% 5% 4% 4% 4% 4% 4% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.041764
GSM967853U87-EV human glioblastoma xenograft - Control 26.2298584
GSM967854U87-EV human glioblastoma xenograft - Control 35.6545980
GSM967855U87-EV human glioblastoma xenograft - Control 41.974634
GSM967856U87-EV human glioblastoma xenograft - Control 51.98774
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.053534
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.02144
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.016954
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.040745
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.017664
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.016414
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.012334
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.010674
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.012834